WEBULL

Cochlear (ASX:COH) Could Be 76% Overvalued After Osia 3 FDA Clearance

Simply Wall St · 2d ago

Cochlear (ASX:COH) is back in the spotlight after receiving FDA clearance for its Osia 3 Sound Processor, a new fully rechargeable bone conduction device that supports the company’s upgrade driven hearing implant model.

See our latest analysis for Cochlear.

Despite the positive headlines around Osia 3, Cochlear’s recent share price return has been mixed. A 30 day gain of about 15.4% contrasts with a year to date share price decline of around 52.8% and a 1 year total shareholder return that is down about 59.1%. This suggests recent product news is arriving against a backdrop of weaker sentiment and reassessment of risk across the wider medtech sector.

If this FDA approval has you thinking about where growth in medical technology could come from next, it may be worth scanning opportunities across 8 healthcare AI stocks

After Cochlear’s sharp share price fall and recent rebound on the Osia 3 news, the real tension is simple: lean into the reset now, or hold back in case sentiment and the valuation reset further before improving.

Most Popular Narrative: 76.1% Overvalued

Cochlear’s last close at A$123.27 sits well above the A$70.00 fair value implied by the most followed narrative, which frames the Osia 3 news against a tougher earnings reset.

There has also been a dramatic recent decline in the company’s share price, which may suggest a potential buying opportunity. The sell-off followed an earnings downgrade, with management citing weaker-than-expected demand, hospital constraints, softer referral rates, and geopolitical risks.

Read the complete narrative.

Want to understand why Cochlear’s fair value is assessed as much lower than today’s price? The key is how this narrative weighs reset earnings, future margins and a more modest profit multiple in contrast to past market optimism. It also highlights which assumptions drive the A$70.00 figure and how they compare with the company’s earlier premium status.

Result: Fair Value of A$70.00 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Cochlear’s narrative could also be challenged if elective surgery volumes recover faster than expected or if new hearing technologies change investor expectations on growth and margins.

Find out about the key risks to this Cochlear narrative.

Another View on Cochlear’s Valuation

The user narrative pegs Cochlear as overvalued at A$123.27 versus a fair value of A$70.00, but our DCF model points in the opposite direction, with an estimated future cash flow value of A$176.48 suggesting the stock is trading below that mark. Which story do you think better fits the risks and cash flows?

Look into how the SWS DCF model arrives at its fair value.

COH Discounted Cash Flow as at Jul 2026
COH Discounted Cash Flow as at Jul 2026

Next Steps

If this mix of caution and opportunity around Cochlear leaves you unsure, it makes sense to act quickly, review the data yourself, and then consider the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Cochlear?

If Cochlear has sharpened your focus on opportunities, do not stop here. Use the Simply Wall St screener to quickly find stocks that better fit your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.